MET+ Expression May Be Predictive of Responses With Amivantamab/Lazertinib in Post-Osimertinib NSCLC onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.
CHICAGO — MET status by immunohistochemistry may predict how patients with osimertinib-treated EGFR-mutated non-small lung cancer will respond to subsequent combination therapy, according to findings presented at ASCO Annual Meeting.Patients with MET-positive status appeared five times as likely as those with MET-negative status to respond to amivantamab (Rybrevant, Janssen) plus lazertinib
Tedopi is the Company's Most Advanced Product in Clinical Development ATALANTE-1, a Phase 3 clinical trial with positive results comparing Tedopi to chemotherapy in non-small cell lung cancer
OSE Immunotherapeutics Presents Clinical Abstracts on Tedopi® at the ASCO 2023 Annual Meeting streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
06.06.2023 - Regulatory News: OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) presented a poster and a publication in abstract book featuring Tedopi, an immunotherapy activating tumor specific T-cells, in non-small cell lung cancer (NSCLC) and in . Seite 1